Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Partial oral treatment of endocarditis

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Coagulation parameters in the newborn and infant - the Copenhagen Baby Heart and COMPARE studies

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Lipoprotein(a) levels at birth and in early childhood: The COMPARE Study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Ticagrelor and the risk of Staphylococcus aureus bacteraemia and other infections

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Lung Ultrasound Findings Associated With COVID-19 ARDS, ICU Admission, and All-Cause Mortality

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Biomarkers of Cerebral Injury for Prediction of Postoperative Cognitive Dysfunction in Patients Undergoing Cardiac Surgery

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations
Guidelines for the treatment of left-sided infective endocarditis (IE) recommend 4 to 6 weeks of intravenous antibiotics. Conversion from intravenous to oral antibiotics in clinically stabilized patients could reduce the side effects associated with intravenous treatment and shorten the length of hospital stay. Evidence supporting partial oral therapy as an alternative to the routinely recommended continued parenteral therapy is scarce, although observational data suggest that this strategy may be safe and effective.
Original languageEnglish
JournalAmerican Heart Journal
Volume165
Issue number2
Pages (from-to)116-22
Number of pages7
ISSN0002-8703
DOIs
Publication statusPublished - Feb 2013

    Research areas

  • Administration, Oral, Adult, Aged, Anti-Bacterial Agents, Dose-Response Relationship, Drug, Endocarditis, Bacterial, Female, Follow-Up Studies, Humans, Injections, Intravenous, Male, Middle Aged, Prospective Studies, Treatment Outcome

ID: 38706968